Key takeaways
Stelara (ustekinumab) and Rinvoq (upadacitinib) are both medications used to treat autoimmune and inflammatory conditions, such as ulcerative colitis and psoriatic arthritis. However, they belong to different medication classes. Stelara is an interleukin antagonist that blocks proteins in your immune system to lower inflammation, while Rinvoq is a Janus kinase (JAK) inhibitor that blocks the JAK enzyme to reduce inflammation. Stelara is given as an injection, either under the skin or through an intravenous (IV) infusion, and is typically administered every 8 to 12 weeks. Rinvoq, on the other hand, is taken orally once a day as a tablet or liquid. Stelara is available for both adults and children as young as 6 years old, while Rinvoq can be used in adults and children as young as 2 years old for certain conditions. Common side effects of Stelara include common cold symptoms and headaches, whereas Rinvoq may cause upper respiratory infections and acne. Both medications can increase your risk of infections. And both medications are available only as brand-name products.
